ON4.MU Ono Pharmaceutical Co. Ltd

Healthcare Pharmaceuticals Munich Exchange
12.81 EUR
Close of Oct 31, 2026
10.15 14.21
Market cap
EUR 6.02B
P/E
14.1x
P/B
1.21x
ROE
11.1%
Dividend yield
3.68%
Fundamental score
3.8/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ON4.MU undervalued?

Graham number
Price12.81
Graham value14.67
Discount12.6%

ON4.MU trades 12.6% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ono Pharmaceutical Co. Ltd fundamental analysis

18 of 22 checks passed

ROE 1/2

Moderate return on equity (11.1%), between 10% and 20%.

ROA 1/1

Return on assets (8.9%) is above the industry median (3.8%).

Profit Consistency 2/2

Profitable for 10 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (39.4%) is above the 5-year average (-0.4% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (39.4%) is above the industry median (14.7%).

Revenue Growth 1/2

Revenue grew 4.9% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (7.8%), 40% or less.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 1/1

EBIT is 40.9x against interest expense, well covered.

PE vs Market 1/1

PE (14.1x) is below the market median (16.6x).

PE vs Industry 1/1

PE (14.1x) is below the industry median (16.6x).

PBV 1/1

Price to book (1.2x) is below the industry median (1.5x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 17.2, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (3.8%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 2/2

Dividends paid without a cut of more than 10% for 11 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 53.8%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Ono Pharmaceutical Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ono Pharmaceutical Co. Ltd

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also p…

Full company profile